Tirzepatide Explored for Automated Blood Sugar Control in Type 1 Diabetes

Adults with Type 1 Diabetes (T1D) face a lifelong challenge managing blood sugar, even with advanced technologies like insulin pumps and continuous glucose monitors (CGMs). A major hurdle is carbohydrate counting, which demands precise estimation of meal carbs to administer correct insulin doses, often leading to suboptimal glycemic control. This study addresses the critical need for simplifying insulin management and improving glucose stability in T1D by reducing or eliminating the burden of carbohydrate counting.

While this is a planned study, researchers hypothesize that tirzepatide, a dual GLP-1 and GIP receptor agonist (which enhances insulin secretion, slows gastric emptying, and reduces glucagon), will significantly improve glycemic control and reduce insulin requirements in Type 1 Diabetes. This improvement is expected to enable the Tandem Control-IQ system to operate effectively without manual carbohydrate announcements, maintaining or improving Time in Range (TIR). Secondary outcomes are anticipated to show a reduction in HbA1c levels, a decrease in the frequency and severity of hypoglycemic episodes, and an overall improvement in patient quality of life due to reduced management burden. > The most significant expected finding is that tirzepatide will allow for fully closed-loop glucose control without manual carbohydrate input, achieving non-inferior or superior Time in Range (TIR) compared to current best practices requiring carb counting.